Clinical Trial Update: Immune-checkpoint Blockade After Partial Breast Irradiation by Pembrolizumab in Early TNBC [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study of pembrolizumab as immune-checkpoint blockade after partial breast irradiation in patients with early trip…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Gangnam Severance Hospital | Conditions: Triple-Negative Breast Neoplasm | Phase 2 | Status: NOT_YET_RECRUITING